8-K: Penumbra Reports Strong Q4 and Full Year 2024 Results, Projects Double-Digit Growth for 2025

Penumbra, Inc. announces positive financial results for Q4 and full year 2024, driven by U.S. thrombectomy product sales, and forecasts continued growth in 2025.

Summary

• Penumbra, Inc. reported its Q4 and full year 2024 financial results.
• Adjusted revenue for Q4 2024 was $321.3 million, a 12.9% increase compared to Q4 2023, excluding a $5.8 million impact from an Italian government payback provision.
• Full year 2024 adjusted revenue reached $1,200.4 million, up 13.4% from 2023, also excluding the Italian payback impact.
• Reported revenue for Q4 2024 was $315.5 million, a 10.8% increase year-over-year.
• Full year 2024 reported revenue was $1,194.6 million, a 12.9% increase compared to the previous year.
• The company's income from operations for Q4 2024 was $42.8 million, with a non-GAAP income from operations of $48.6 million.
• For the full year 2024, income from operations was $9.3 million, and non-GAAP income from operations was $106.6 million.
• Net income for Q4 2024 was $33.7 million, with an adjusted EBITDA of $63.7 million.
• Full year 2024 net income was $14.0 million, and adjusted EBITDA was $171.0 million.
• The company projects total revenue for 2025 to be in the range of $1,340.0 million to $1,360.0 million, representing year-over-year growth of 12% to 14%.

Sentiment

Score: 8

Explanation: The report is positive due to strong revenue growth, particularly in the U.S. market, and optimistic projections for 2025. While there are some negative aspects, such as decreased international revenue and impairment charges, the overall tone is confident and forward-looking.

Positives

• Strong revenue growth in both Q4 and full year 2024, driven by U.S. thrombectomy product sales.
• Significant increase in U.S. revenue, indicating strong market penetration and demand.
• Projected revenue growth of 12% to 14% for 2025, demonstrating confidence in future performance.
• Expected gross margin expansion of at least 100 basis points in 2025, indicating improved profitability.
• Operating margin is projected to expand to a range of 13% to 14% of revenue for full year 2025.

Negatives

• International revenue decreased by 9.4% in Q4 2024 on an adjusted basis, indicating challenges in overseas markets.
• Full year 2024 income from operations was $9.3 million, significantly lower than the $73.6 million reported in 2023.
• The company incurred a one-time $33.4 million inventory impairment charge related to its Immersive Healthcare asset group.
• The company incurred a $76.9 million long-lived asset impairment charge associated with the impairment of assets related to our Immersive Healthcare business.

Risks

• Failure to sustain or grow profitability or generate positive cash flows.
• Delays in product introductions.
• Significant competition in the thrombectomy market.
• Inability to achieve or maintain satisfactory pricing and margins.
• Potential adverse regulatory actions.

Future Outlook

The company projects total revenue for 2025 to be in the range of $1,340.0 million to $1,360.0 million, representing year-over-year growth of 12% to 14%. The Company projects the U.S. thrombectomy franchise will grow 19% to 20% year-over-year, driven primarily by its computer assisted vacuum thrombectomy (CAVT) products. The Company expects gross margin expansion of at least 100 basis points in 2025, to more than 67% for the full year, and operating margin expansion to a range of 13% to 14% of revenue for full year 2025.

Industry Context

Penumbra's focus on thrombectomy solutions aligns with the growing demand for minimally invasive procedures in treating vascular diseases. The company's strong U.S. performance reflects the increasing adoption of its CAVT technology. The projected growth in 2025 indicates Penumbra's ability to capitalize on market opportunities and maintain its leadership position.

Comparison to Industry Standards

• Comparing Penumbra to companies like Stryker and Medtronic, which also have vascular intervention segments, Penumbra's growth rate in thrombectomy is competitive.
• Stryker reported organic sales growth of 11.5% in 2024, while Medtronic's cardiovascular portfolio saw a 5.4% increase.
• Penumbra's projected revenue growth of 12-14% for 2025 positions it favorably against these larger, more diversified competitors in the specific area of thrombectomy.
• The gross margin expansion target of 100 basis points is also a positive sign, as it indicates improved operational efficiency and pricing power, aligning with industry benchmarks for medical device companies.

Stakeholder Impact

• Shareholders can expect continued growth and potential for increased profitability.
• Employees may benefit from the company's expansion and success.
• Customers will have access to innovative thrombectomy technologies.
• Suppliers can anticipate increased demand for Penumbra's products.

Next Steps

• The company will host a conference call on February 18, 2025, to discuss the financial results.
• Penumbra expects to file its Annual Report on Form 10-K on or before March 3, 2025.

Key Dates